TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
Earnings
TScan Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$600.00K
-76.0% on a year earlier
EPS, Q3 FY2026
-$0.25
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of TScan Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 3, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | $600.00K | -76.0% | -$0.25 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | $1.10M | -64.5% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $1.00M | -54.5% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 4, 2026before the open | $2.60M | +271.4% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $2.50M | +150.0% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | $3.10M | +520.0% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | $2.20M | +266.7% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025before the open | $700.00K | -90.3% | -$0.30 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $1.00M | -74.4% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024before the open | $500.00K | -83.9% | -$0.28 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024before the open | $600.00K | -91.2% | -$0.32 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 6, 2024before the open | $7.20M | +132.3% | -$0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $3.90M | +14.7% | -$0.24 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023before the open | $3.10M | -24.4% | -$0.51 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | $6.80M | +126.7% | -$0.93 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023before the open | $3.10M | – | -$0.78 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022before the open | $3.40M | +41.0% | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022before the open | $4.10M | – | -$0.63 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022before the open | $3.00M | – | -$0.67 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 9, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $2.41M | – | -$0.80 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 19, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
TScan Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When TScan Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases TScan Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- Update
- Update
- Update
- Results
- Results
See a number that looks wrong?